Cardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and Drug Administration (FDA) instituted a new requirement that new drugs developed and studied for the treatment of T2D must undergo CV safety testing. Since the advent of this new policy, canagliflozin, empagliflozin, liraglutide and semaglutide have demonstrated superior CV event reduction – via a composite of reduction in CV death, nonfatal myocardial infarction (MI), and nonfatal stroke – compared with placebo in patients with T2D and existing CVD, or at high risk of CVD. Multiple studies are underway to evaluate the CV outcomes of other antihyperglycemic agents. In a time when there are numerous drugs in the T2D armamentarium, positive CV outcomes data influence drug selection and aids practitioners in making more individualised therapeutic recommendations for their patients.
Diabetes, cardiovascular disease,
antihyperglycemic, glucagon-like peptide-1
receptor agonists (GLP-1) receptor
agonists, sodium-glucose cotransporter-2
Sarah L Anderson and Joel C Marrs have
nothing to declare in relation to this article. No funding
was received in the publication of this article. This study
involves a review of the literature and did not involve any
studies with human or animal subjects performed by
any of the authors.
Sarah L Anderson;
Mail Stop C238, 12850 E. Montview Blvd.,
room V20-2129, Aurora, Colorado, 80045, US.
This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.
Share this Article
Related Content In Diabetes
Controversies in Gestational Diabetes
touchREVIEWS in Endocrinology. 2021;17(2):Online ahead of journal publication.
Gestational diabetes mellitus (GDM), defined as hyperglycaemia identified after the first trimester of pregnancy that is not clearly overt diabetes, impacts approximately 7% of births in the USA; a percentage that has increased in parallel with the prevalence of both obesity and type 2 diabetes over the past 20 years.1–4 The impacts of GDM include hypertensive […]
The DFUC 2020 Dataset: Analysis Towards Diabetic Foot Ulcer Detection
touchREVIEWS in Endocrinology. 2021;17(1):5–11 DOI: https://doi.org/10.17925/EE.2021.17.1.5
Wounds on the feet, known as diabetic foot ulcers (DFUs), are a major complication of diabetes. DFUs can become infected, leading to amputation of the foot or lower limb. Patients who undergo amputation experience significantly reduced survival rates.1 In previous studies, researchers have achieved high accuracy in the recognition of DFUs using machine learning algorithms.2–5 […]
Diabetes Mellitus of Pituitary Origin: A Case Report
touchREVIEWS in Endocrinology. 2021;17(1):68–70 DOI: https://doi.org/10.17925/EE.2021.17.1.68
Acromegaly is a chronic, progressive disease characterized by an excess secretion of growth hormone, and consequently, increased circulating insulin-like growth factor 1 (IGF-1) levels. These patients typically exhibit acral and soft tissue overgrowth, headache, arthritis and visual disturbances. Impaired glucose tolerance and diabetes mellitus are also frequently associated with acromegaly.1 We describe a patient who […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!